These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28975475)

  • 1. Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.
    Parikh KS; Piccini JP
    Curr Heart Fail Rep; 2017 Dec; 14(6):529-535. PubMed ID: 28975475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    Piccini JP; Connolly SJ; Abraham WT; Healey JS; Steinberg BA; Al-Khalidi HR; Dignacco P; van Veldhuisen DJ; Sauer WH; White M; Wilton SB; Anand IS; Dufton C; Marshall DA; Aleong RG; Davis GW; Clark RL; Emery LL; Bristow MR
    Am Heart J; 2018 May; 199():51-58. PubMed ID: 29754666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
    Piccini JP; Abraham WT; Dufton C; Carroll IA; Healey JS; van Veldhuisen DJ; Sauer WH; Anand IS; White M; Wilton SB; Aleong R; Rienstra M; Krueger SK; Ayala-Paredes F; Khaykin Y; Merkely B; Miloradović V; Wranicz JK; Ilkhanoff L; Ziegler PD; Davis G; Emery LL; Marshall D; Kao DP; Bristow MR; Connolly SJ;
    JACC Heart Fail; 2019 Jul; 7(7):586-598. PubMed ID: 31042551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.
    Black-Maier E; Steinberg BA; Piccini JP
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):627-36. PubMed ID: 25959096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
    Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
    Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
    Kao DP; Davis G; Aleong R; O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Murphy GA; Sauer W; Bristow MR
    Eur J Heart Fail; 2013 Mar; 15(3):324-33. PubMed ID: 23223178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the
    Piccini JP; Dufton C; Carroll IA; Healey JS; Abraham WT; Khaykin Y; Aleong R; Krueger SK; Sauer WH; Wilton SB; Rienstra M; van Veldhuisen DJ; Anand IS; White M; Camm AJ; Ziegler PD; Marshall D; Bristow MR; Connolly SJ;
    Circ Arrhythm Electrophysiol; 2021 Aug; 14(8):e009591. PubMed ID: 34270905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.
    Rosa GM; Meliota G; Brunelli C; Ferrero S
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):473-481. PubMed ID: 28162002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.
    Aleong RG; Sauer WH; Davis G; Murphy GA; Port JD; Anand IS; Fiuzat M; O'Connor CM; Abraham WT; Liggett SB; Bristow MR
    JACC Heart Fail; 2013 Aug; 1(4):338-344. PubMed ID: 24159564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
    Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.
    Cadrin-Tourigny J; Shohoudi A; Roy D; Talajic M; Tadros R; Mondésert B; Dyrda K; Rivard L; Andrade JG; Macle L; Guerra PG; Thibault B; Dubuc M; Khairy P
    JACC Heart Fail; 2017 Feb; 5(2):99-106. PubMed ID: 28089316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
    Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
    J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
    Liggett SB; Mialet-Perez J; Thaneemit-Chen S; Weber SA; Greene SM; Hodne D; Nelson B; Morrison J; Domanski MJ; Wagoner LE; Abraham WT; Anderson JL; Carlquist JF; Krause-Steinrauf HJ; Lazzeroni LC; Port JD; Lavori PW; Bristow MR
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11288-93. PubMed ID: 16844790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
    Alkhatib N; Sweitzer NK; Lee CS; Erstad B; Slack M; Gharaibeh M; Karnes J; Klimecki W; Ramos K; Abraham I
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):205-217. PubMed ID: 32710439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms.
    O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Walsh R; Nelson P; Medway A; Davis G; Robertson AD; Port JD; Carr J; Murphy GA; Lazzeroni LC; Abraham WT; Liggett SB; Bristow MR
    PLoS One; 2012; 7(10):e44324. PubMed ID: 23071495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.
    Li SJ; Sartipy U; Lund LH; Dahlström U; Adiels M; Petzold M; Fu M
    Circ Heart Fail; 2015 Sep; 8(5):871-9. PubMed ID: 26243796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
    Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
    Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
    Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
    Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.
    Mordi IR; Santema BT; Kloosterman M; Choy AM; Rienstra M; van Gelder I; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Metra M; Ng LL; Ouwerkerk W; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Zannad F; Voors AA; Lang CC
    Clin Res Cardiol; 2019 Jul; 108(7):797-805. PubMed ID: 30610382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.